A Single and Multiple Dose Study to Explore the Safety of JNJ-38224342 in Healthy Patients and Patients With Seasonal Allergies

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT01054352
First received: January 21, 2010
Last updated: September 3, 2013
Last verified: September 2013

January 21, 2010
September 3, 2013
February 2010
Not Provided
To assess safety and pharmacokinetics of single and multiple oral ascending doses of JNJ-38224342 with and without food in healthy volunteers and patients with seasonal allergies as determined by occurrence of adverse events, lab test results, vital sign [ Time Frame: from the time of the first dose to 7-11 days after the last dose administered ] [ Designated as safety issue: No ]
To assess safety and pharmacokinetics of single and multiple oral ascending doses of JNJ-38224342 with and without food in healthy volunteers and patients with seasonal allergies as determined by occurance of adverse events, lab test results, vital sign [ Time Frame: from the time of the first dose to 7-11 days after the last dose administered ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01054352 on ClinicalTrials.gov Archive Site
  • Evaluate the results of biomarker assessments performed during Parts 2 and 4 of the trial. [ Time Frame: from 7-11 days post the last administered dose ] [ Designated as safety issue: No ]
  • Evaluate the effectiveness of treatment based on nasal symptoms for Part 4. [ Time Frame: from 7-11 days post the last administered dose ] [ Designated as safety issue: No ]
  • Evaluate the results of biomarker assessments performed during Parts 2 and 4 of the trial. [ Time Frame: from 7-11 days post the last administered dose ] [ Designated as safety issue: No ]
  • Evaluate the effectiveness of treatement based on nasal symptoms for Part 4. [ Time Frame: from 7-11 days post the last administered dose ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Single and Multiple Dose Study to Explore the Safety of JNJ-38224342 in Healthy Patients and Patients With Seasonal Allergies
A Double-blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics and Pharmacodynamics of JNJ-38224342 in Healthy Patients and in Healthy Patients With Seasonal Allergic Rhinitis

A single and multiple dose study to assess the safety of JNJ 38224342 compared to placebo in healthy volunteers and in volunteers with seasonal allergies.

A four-part, single and multiple dose study to investigate the safety of JNJ-38224342 versus placebo in healthy patients and in patients with seasonal allergies. Volunteers (or patients) are randomly assigned to one of four treatment groups or Parts. Part 1 and 2 are randomized (study drug will be assigned by chance) and double-blind (neither the physician nor volunteer knows the identity of the assigned drug). In Part 1 patients receive a single oral dose of either 25, 100, 300, 600, 1250 or 2000 mg of JNJ-38224342 or placebo. In Part 2 patients receive multiple oral doses of either 100, 250, 500 or 700 mg of JNJ-38224342 or placebo administered over 14 days. Part 3 (for male volunteers only) is open-label (all people involved know the identity of the assigned drug), 2-period crossover (meaning that volunteers will receive both treatments at different times) study of the effects of food on JNJ-38224342. Participants will be given a single 100 mg oral dose (either solution or capsule formulation). Part 4 is for patients with seasonal allergies only. The dose of JNJ-38224342 will be determined based on information collected in Parts 1 - 3. Patients that participate in part 4 of the study will also have their nasal passage flushed out with salt water and the contents will be collected. Patients will be asked to remain in the clinic for either 5 days or 18 days depending on what part of the study they are participating in. A physical exam will be performed and a medical history collected. Safety evaluations include adverse event monitoring, blood pressure measurements, ECG and lab work requiring blood and urine samples at various time points throughout the study. Single oral dose of either 25, 100, 300, 600, 1250 or 2000mg of JNJ-38224342 or placebo; Multiple oral dose of either 100, 250, 500 or 700 mg of JNJ-38224342 or placebo administered over 14 days; single oral 100mg dose of JNJ 38224342 as a solution versus capsule with or without food; multiple oral doses of JNJ38224342 or placebo administered for up to 14 days where the number of days dosed, actual dose levels, food requirements will be determined based on the data from Parts 1, 2, and 3

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Seasonal Allergic Rhinitis
  • Drug: JNJ38224342
    multiple ascending oral doses (100, 250, 500, 750 mg) of JNJ 38224342 or matching placebo, administered for 14 consecutive days in healthy male or female volunteers
  • Drug: JNJ38224342/placebo
    up to four (4) additional cohorts consisting of healthy male volunteers may be added
  • Drug: JNJ38224342/placebo
    .up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
  • Drug: JNJ38224342/placebo
    one of six (6) single ascending doses (25, 100, 300, 600, 1250 or 2000 mg) of JNJ 38224342 or matching placebo
  • Experimental: 001
    JNJ38224342/placebo one of six (6) single ascending doses (25 100 300 600 1250 or 2000 mg) of JNJ 38224342 or matching placebo up to four (4) additional cohorts consisting of healthy male volunteers may be added
    Intervention: Drug: JNJ38224342/placebo
  • Experimental: 002
    JNJ38224342/placebo multiple ascending oral doses (100 250 500 750 mg) of JNJ 38224342 or matching placebo administered for 14 consecutive days in healthy male or female volunteers.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
    Intervention: Drug: JNJ38224342/placebo
  • Experimental: 003
    JNJ38224342 single oral 100mg dose of JNJ 38224342 as a solution versus a single oral dose of JNJ 38224342 as a capsule formulation with and without food in healthy male volunteers
    Intervention: Drug: JNJ38224342
  • Experimental: 004
    JNJ38224342/placebo multiple oral doses of JNJ38224342 or matching placebo administered for up to 14 consecutive days in male and female volunteers number of days dosed and actual dose levels food requirements and regimens will be determined based on the data from Parts 1 2 and 3.
    Intervention: Drug: JNJ38224342/placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
182
March 2011
Not Provided

Inclusion Criteria:

  • Non-smokers
  • If male, willing to use an acceptable method of birth control for duration of study and for 90 days post study
  • Females must be post menopausal, surgically sterilized and cannot be pregnant or lactating (all parts of study)
  • Have a clinical history of allergic rhinitis during the ragweed pollen season and a positive skin test for ragweed allergy are required (for part 4 of study only)

Exclusion Criteria:

  • Clinically significant medical illnesses, laboratory or ECG findings
  • History of allergy to aspirin or nonsteroidal anti-inflammatory drugs
  • history of alcohol or drug abuse within the last 5 years
  • HIV or Hepatitis B or C positive
  • Receipt of an investigational drug or use of an investigational medical device within the last month
  • History of asthma or severe respiratory infection or disorder
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT01054352
CR016798
No
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Not Provided
Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP